A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)

NCT00891735 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1097

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-related Macular Degeneration

Interventions

DRUG: Ranibizumab

Sponsor

Genentech, Inc.